Lead Product(s) : Empagliflozin,Linagliptin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alkem Launches Generic Empagliflozin and Its Combinations in India Under ‘Empanorm’
Details : Empanorm L (empagliflozin-linagliptin) is an SGLT-2/DPP-4 inhibitor indicated for use in the treatment of type-2 diabetes mellitus, CKD and chronic heart failure (HF).
Product Name : Empanorm L
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2025
Lead Product(s) : Empagliflozin,Linagliptin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin,Linagliptin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Glenmark Pharma Launches Empagliflozin and Its Fixed-Drug Combinations in India
Details : Glempa-L (empagliflozin-linagliptin) is an SGLT-2/DPP-4 inhibitor indicated for use in the treatment of type-2 diabetes mellitus, CKD and chronic heart failure (HF).
Product Name : Glempa-L
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2025
Lead Product(s) : Empagliflozin,Linagliptin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin,Linagliptin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin receives US FDA tentative marketing approval for generic Trijardy XR tablets
Details : Trijardy XR-Generic is a combination product of empagliflozin, linagliptin & metformin hydrochloride which is indicated for the treatment of adults with type 2 diabetes mellitus.
Product Name : Trijardy XR-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 07, 2024
Lead Product(s) : Empagliflozin,Linagliptin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linagliptin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : $28.3 million
Deal Type : Acquisition
Lupin Acquires Brands ONDERO® and ONDERO MET® to Expand Diabetes Portfolio in India
Details : Through the acquisition, Lupin expands its diabetes portfolio in India by gaining access to Ondero (linagliptin) and Ondero Met (linagliptin & metformin). Ondero is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes...
Product Name : Ondero
Product Type : Other Small Molecule
Upfront Cash : $28.3 million
August 18, 2023
Lead Product(s) : Linagliptin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : $28.3 million
Deal Type : Acquisition
Lead Product(s) : Linagliptin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
USV Launches Liralin Range for Diverse Group of Type 2 Diabetes Patients
Details : Liralin (linagliptin) is a DPP-4 (Dipeptidyl peptidase IV) inhibitor, oral small molecule drug which is approved for the treatment of type-2-diabetes mellitus.
Product Name : Liralin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2023
Lead Product(s) : Linagliptin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
